


eTable 1 Characteristics of the patients

	TAO patients	Healthy controls	P value
	n=30	n=38	
Age , y	45.23±11.92	46.54±18.04	0.9557
Sex (Female/Male)	22/8	26/12	0.659
Duration of disease, y	2.46±4.39	N/A	
Treatment history (n , %)		N/A	
None	12 (40%)		
Steroids	15 (50%)		
Decompression Surgery	2 (6.7%)		
Secukinumab	1 (3.3%)		
Thyroid function (n , %)		N/A	
Hyperthyroidism	16 (53.3%)		
Hypothyroidism	7 (23.3%)		
Euthyroidism	7 (23.3%)		
Activity (n , %)		N/A	
Active phase	19 (63.3%)		
Inactive phase	11 (36.7%)		
Severity (n , %)		N/A	
Moderate to severe	24 (80.0%)		
Severe	6 (20.0%)		
Axial Length mm	24.40±1.58	24.21±1.09	0.5865
Proptosis mm	20.28±3.00	14.72±1.50	P < 0.001
IOP mmHg	19.51±4.40	16.91±3.97	P < 0.01
BCVA	0.77 ±0.29	0.85 ±0.17	0.6187

eFigure 1 a. Comparisons of the SFCT based on SS-OCT image measurements between patients with active, inactive TAO group and healthy subjects. b. Comparisons of SFCT between mild, moderate to severe, severe TAO group and healthy subjects



eTable 2 Multivariate linear regression using SFCT as dependent factor in TAO patients

Coefficients^a

Model	Unstandardized Coefficients		Standardized Coefficients	t	Sig.	Correlations	
	B	Std. Error	Beta			Zero-order	Partial
(Constant)	977.346	166.827		5.858	.000		
Age	-.496	.694	-.061	-.714	.479	.034	-.099
Duration	.061	2.151	.003	.029	.977	-.374	.004
Proptosis	1.491	2.743	.045	.544	.589	-.121	.075
CAS	21.681	8.972	.224	2.417	.019	.531	.318
BCVA	105.106	35.632	.290	2.950	.005	.115	.379
IOP	8.277	2.146	.370	3.856	.000	.313	.472
AL	-43.339	6.022	-.612	-7.197	.000	-.730	-.706